Gain Real-Time Insights on High-Risk Patient Populations with Real-World Data

A leading multiple myeloma manufacturer used Norstella’s real-world data solutions, powered by NorstellaLinQ, to identify high-risk patients and the physicians treating them. By combining EHR, lab, and claims data, the company gained actionable insights that improved HCP targeting, accelerated patient identification, and drove more informed treatment decisions. The company:

Identified newly diagnosed and relapsed high-risk patients using delivered, leading to genomic and EHR data
Improved outreach to healthcare providers likely to treat these specific patient populations
Generated actionable alerts to engage HCPs and guide critical treatment conversations

Key Results

2K+

Actionable Field Alerts Delivered

800

Newly Identified Patients

Challenge

A pharmaceutical company faced a significant challenge in identifying high-risk patients for specific therapies, particularly those with certain genomic profiles crucial to effective treatment. The company needed greater visibility into which patients were appropriate for therapy, as well as a clear picture of the physicians treating these patients.

The manufacturer’s primary goal was to accurately identify newly diagnosed and relapsed patients with specific genetic markers to help guide physician treatment decisions. However, they struggled due to a lack of in-depth genomic data, which prevented the identification of patient profiles necessary to define their high-risk population.

Solution

Norstella collaborated with the company to address these challenges. By integrating and analyzing extensive datasets— including EHRs, lab results, and claims data—Norstella helped the company develop detailed patient profiles. These profiles focused on newly diagnosed multiple myeloma patients and those with early-stage conditions, facilitating targeted identification of patients based on specific genetic markers and risk factors.

Norstella delivered more than 2,000 actionable field alerts to the company, enabling the identification of new high-value HCPs and patients. The field alerts contained insights on high-risk and ultra-high-risk patients, helping the company communicate critical treatment information to the appropriate physicians. Additionally, Norstella provided weekly reports, which matched patients to specialty providers with a 90% success rate.

Outcome

Through this partnership, Norstella’s data solution helped the manufacturer achieve a deeper understanding of their patient populations and significantly improve physician engagement. The project yielded more than 2,000 actionable triggers, leading to productive conversations with HCPs and the identification of 800 newly diagnosed patients.

These insights allowed the manufacturer to better meet their inclusion and exclusion criteria for patient profiles, leading to improved national provider identifier (NPI)-level reporting and targeted physician engagement. The outcome not only led to higher patient conversions to the manufacturer’s therapy, but also helped the manufacturer make more informed, data-driven decisions, opening doors for future use cases and collaboration opportunities.

Get Started

Get Closer to the Patient Than Ever Before

NorstellaLinQ links claims, EHR, lab, and electronic prescription data into a single patient view — decision-grade and AI-ready. See what it can do for your team.

Frequently asked questions

Everything You Need to Know

How can real-world data help identify high-risk patient populations?

Real-world data combines EHR, laboratory, and claims data to create detailed patient profiles, enabling pharmaceutical companies to identify high-risk patients based on clinical and genomic characteristics that may not be visible through a single data source.

How does integrated healthcare data improve physician targeting?

By linking patient data with treating provider information, integrated real-world data helps manufacturers identify the healthcare professionals caring for high-risk patients, enabling more targeted and timely engagement.

What role do actionable field alerts play in patient identification?

Actionable field alerts notify commercial teams when newly identified high-risk patients and their treating physicians meet specific criteria, helping facilitate timely treatment discussions and more informed physician engagement.

How did Norstella improve high-risk patient identification in this case study?

Norstella integrated EHR, laboratory, and claims data to identify newly diagnosed and relapsed multiple myeloma patients with specific genetic markers. The solution delivered more than 2,000 actionable field alerts and identified 800 newly diagnosed patients.

What business outcomes did the manufacturer achieve?

The manufacturer gained deeper visibility into high-risk patient populations, improved physician engagement, enhanced NPI-level reporting, increased patient conversions to therapy, and made more informed data-driven decisions for future commercial initiatives.